Wells David R. 4
4 · ENDRA Life Sciences Inc. · Filed Dec 11, 2019
Insider Transaction Report
Form 4
Wells David R.
Chief Financial Officer
Transactions
- Award
Stock option (right to buy)
2019-12-11+138,375→ 138,375 totalExercise: $0.90Exp: 2029-12-11→ Common Stock (138,375 underlying) - Award
Series A Convertible Preferred Stock
2019-12-11$1143.68/sh+8.744$10,000→ 8.744 totalExercise: $0.87From: 2019-12-11→ Common Stock (10,051 underlying) - Award
Warrants
2019-12-11+10,051→ 10,051 totalExercise: $0.87From: 2019-12-11Exp: 2024-12-11→ Common Stock (10,051 underlying)
Footnotes (4)
- [F1]These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date.
- [F2]The Series A preferred stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A preferred stock is convertible into common stock at a price per share of $0.87.
- [F3]The Series A preferred stock has no expiration date.
- [F4]The Warrants were issued for no additional consideration in connection with the purchase of the Series A preferred stock.